An observational study in COVID-19, sponsored by Johan Normark. Active, not recruiting at 4 sites in Sweden. Open to participants aged 15 Years to 100 Years. Per ClinicalTrials.gov, last updated 2023-12-14.
Sponsored by Johan Normark · Observational
The project aims to clarify how immunity to SARS-CoV2 develops in humans and to investigate the possibility of finding patients with a particularly effective, neutralizing antibody response for future treatment. The project also aims to detail the virus's damage mechanisms in tissue.
There is currently a mounting body of evidence regarding the pathogenesis of COVID-19 caused by SARS-CoV2. By gaining more knowledge about the mechanisms in the development of viral pneumonia and the influence of other organ systems at SARS-CoV2, we believe that in the future it is better to be able to identify precisely those persons who are at risk of serious illness. To this we will gain knowledge of how humans develops immunity to the virus and also how human epigenetic (acquired) ability to activate inflammatory genetic systems can limit the harmful effects of the virus. Thus, patients who have had mild or no symptoms are just as interesting from a study point of view as those who have had severe symptoms. Hopefully, such understanding can also contribute to other opportunities for targeted treatment (by identifying patients who can mount effective inborn and adaptive host defenses) in order to prevent severe disease and death in pandemic corona infection.
7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.
This study's enrollment of 550 is above the median of 261 across 3,136 observational studies indexed under COVID-19.
Browse COVID-19 studies →This is the only study on the registry with Johan Normark as lead sponsor.
Counted across the registry records on this site, refreshed daily.
A mixed population of individuals suffering from Covid-19 or influenza
Exclusion Criteria:
The difference from the standard of care is extended sample collection and study related procedures during the study.
Procedure: Extended sampling and procedures
The study patients will give additional blood samples and also urine and faeces samples. Spirometry and additional biometric controls will be performed regularly. Necrobiopsies of various organs from deceased patients will be secured and stored for immunohistological and virological analysis.
Mortality
Deceased or alive at five year follow-up
Time frame: Five years after study start
Plan to share: No
This study is active, not recruiting, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.